BACKGROUND: Fibroblast growth factor 9 (FGF9) enhances cell proliferation and invasiveness in several malignant diseases. The aim of the present study is to investigate the role of FGF9 in postoperative recurrence after radical prostatectomy.
Introduction
Communication between epithelial and stromal compartments via fibroblast growth factor (FGF) family signaling pathways are thought to have important roles in homeostasis of the normal prostate and disruption of the FGF-signaling pathway causes failure of tissue homeostasis and development of malignant disease. 1, 2 Among FGF family, FGF9 may induce mitogenic activity in prostate epithelial cells. 3 Previous studies have reported association with FGF9 in several malignant diseases. FGF9 has growth-stimulatory effects in glioma. 4 FGF9 is a downstream target of the Wnt-signaling pathway in ovarian endometrioid adenocarcinoma. 5 Lung cancer shows acceleration of tumor growth by aryl hydrocarbon receptor through upregulation of FGF9 expression aryl hydrocarbon receptor. 6 These evidences indicate that FGF9 can be one of the key molecules for development and progression of malignant diseases. Prostate cancer is one of the most common malignant neoplasms among men, and is the second leading cause of male cancer death in the United States. 7 Although radical prostatectomy is the standard treatment option for clinically localized prostate cancer worldwide, including Japan, postoperative recurrence is not uncommon. Several studies have demonstrated that the expression and polymorphism of specific genes are predictive factors for postoperative recurrence. For instance, the expression level of vascular epithelial growth factor-A and -C are prognostic factors for clinical outcome after radical prostatectomy. 8 Epidermal growth factor receptor 9 and p53 10 polymorphism have been reported to be predictive factors for biochemical recurrence after radical prostatectomy. Identification of novel predictive factors for postoperative recurrence through elucidating the molecular mechanism for progression of prostate cancer is a very important issue in prostate cancer research.
The objectives of the present study were to determine the effect of FGF9 on the progression of prostate cancer cells in vitro and to explore the impact as a predictive factor of recurrence after radical prostatectomy owing to prostate cancer.
Materials and methods

Cell culture
LNCaP cells were purchased from the American Type Culture Collection (Manassas, VA, USA), and maintained in RPMI-1640 medium supplemented with 10% heatinactivated FBS (Life Technologies, NY, USA). Cells were maintained at 37 1C in a humidified atmosphere of 5% CO 2 , 95% air. Culture media were changed every 48 h.
MTT assay
LNCaP cells were plated in 96-well plates (2 Â 10 3 cells per well) with 100 ml of RPMI-1640 medium containing 2.5% charcoal-stripped FBS, and incubated at 37 1C in a humidified atmosphere of 5% CO 2 , 95% air overnight. The media was replaced with RPMI-1640 medium containing 2.5% charcoal-stripped FBS and 1 or 10 nM recombinant FGF9 (R&D Systems, Minneapolis, MN, USA), 11 or not containing FGF9, respectively. MTT solution was added after 4 days and the plates were incubated at 37 1C for 3 h. The plates were analyzed using an ELISA plate reader (Bio-Rad, Hercules, CA, USA) at 570 nm with the reference wave length of 630 nm. To confirm the effects of FGF9, the same experiment was performed in addition to 100 mg ml
À1
of FGF9-neutralizing antibody (R&D Systems) 11 in every well. Each experiment was repeated three times and the data were recorded as the mean and s.d.
Matrigel invasion assay
Cell migration assays were performed in 6.4 mm diameter chambers with 8 mm pore filters coated with Matrigel (Matrigel Invasion Chamber, Transwell, 24-well cell cultures; Becton-Dickinson, Bedford, MA, USA) as described previously. 12 LNCaP cells were suspended at a concentration of 6 Â 10 5 cells per ml in serum-free RPMI-1640 medium, and 200 ml of the cell suspension was added to the upper chamber. Various concentrations of FGF9 (0, 1 or 10 ng ml À1 ) in 600 ml serum-free RPMI-1640 medium were applied in the lower chamber. The chambers were incubated for 48 h, and the upper surface of the filter was scraped with a cotton swab to remove non-migrating cells, and then the lower surface of the membrane containing the cells that had migrated was stained (Diff-Quick Fixative, Kokusai Shinyaku, Tokyo, Japan). The stained cells were counted in three independent fields for each well under a light microscope ( Â 200). To confirm the effects of FGF9, the same experiment was performed in addition to 100 mg ml
À1
of FGF9-neutralizing antibody in every chamber. The experiments were performed in triplicate wells and were repeated several times.
Western blot analysis
Western blot analysis was performed as described previously. 13, 14 To examine whether FGF9 induces matrix metalloproteinase 2 (MMP2), cells were cultured RPMI-1640 medium containing 0.2% charcoal-stripped FBS for 24 h and were incubated in medium with or without FGF9 (100 ng ml À1 ), for 1, 3 and 5 days. Cells were scraped in Tris-Glysine SDS sample buffer (Invitrogen, Carlsbad, CA, USA). Supernatant protein was electrophoresed on sodium dodecylsulfate polyacrylamide gel electrophoresis gels and electrotransferred onto a nitrocellulose filters. Filters were incubated for 1 h at room temperature with anti-MMP2 antibody (Abcam, Tokyo, Japan), and peroxidase-conjugated anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used in the secondary reaction. Immunocomplexes were visualized with an ECL Western Blot Detection System (Amersham Biosciences, Piscataway, NJ, USA). b-actin (SIGMA, St Louis, MO, USA) was also stained as a loading control.
Immunohistochemical staining
Samples were obtained from tissue resected during radical prostatectomy owing to a diagnosis of prostate cancer with no prior therapy. All human tissues have been used after agreement of each patients through the paperwork ethically approved in our institute. All sections were from formalin-fixed, paraffin-embedded tissue specimens. Samples derived from one representative section in every tissue were stained with anti-FGF9 antibody (R&D Systems).
Immunohistochemical analysis was performed with a Dako Envision þ Mouse Peroxidase Detection System (Dako Cytomation, Carpinteria, CA, USA) as described previously. [11] [12] [13] The sections were deparaffinized in xylene before rehydration in 100, 70 and 50% ethanol and finally water. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide-methanol, and the slides were placed in water before antigen retrieval using a microwave in a 0.01-M citrate buffer (pH 6.0) for 20 min. The sections were placed in normal goat serum (Dako Cytomation) for 1 h to block non-specific antibody binding sites. The primary antibodies were diluted 1:200 then applied to the sections and incubated at 4 1C overnight. The sections were then washed in PBS before incubation with peroxidase-labeled anti-goat IgG (Dako Cytomation) for 1 h at room temperature. The sections were washed in PBS, immunoreactivity was visualized using a Dako Envision kit (Dako Cytomation) according to the manufacturer's instructions, and then counterstained with Harris hematoxylin, before dehydration with graded, and ethanol and xylene before being mounted with a cover slide. When cancer cells with accumulation of FGF9 in cytoplasm were detected, the cases were defined as 'FGF9-positive'. Immunoreactivity of N-cadherin in FGF9-positive tissues was examined using anti N-cadherin antibody (Santa Cruz Biotechnology, diluted 1:50 in PBS) in the same procedures. All slides were read independently by two investigators and classified according to the existence of FGF9-positive cells. The relationships between the existence of FGF9-positive cells and pathological features or clinical course were elucidated.
Definition of biochemical relapse
Serum PSA was tested in every patient after radical prostatectomy by using ECLIA method (Roche Diagnostics, Tokyo, Japan), and biochemical relapse was defined when serum PSA elevated to higher than 0.2 ng ml À1 . If serum PSA did not decline to lower than 0.2 ng ml À1 , the time of biochemical relapse was defined as the day of operation. 
Statistical analysis
The results of the MTT assay and Matrigel invasion assay were analyzed using the Mann-Whitney's U test. The relationship between FGF9 immunohistochemical staining and clinicopathological findings or biochemical relapse-free survival rate was analyzed using the w 2 -test and Log rank test, respectively. Postoperative predictive factors were analyzed using a Cox hazard analysis. All statistical analysis were conducted using StatView 5.0 software package (SAS Institute, Cary, NC, USA). A P-value of less than 0.05 was considered to be statistically significant.
Results
FGF9 promotes cell growth of androgen-dependent prostate cancer cells
An MTT assay was performed to determine the effect of FGF9 on cell growth of LNCaP cells. Figure 1a shows fold induction of cell viability on the 4th day in comparison with those on the 1st day. Figure 1a demonstrates that cell viability of LNCaP was significantly enhanced by treatment with FGF9 in a dosedependent manner, and Figure 1b shows that the effect was significantly suppressed by treatment with anti-FGF9-neutralizing antibody.
FGF9 promotes invasion of prostate cancer cells through matrigel
The chemotactic effect of FGF9 on LNCaP was analyzed using a migration assay through filters coated with the extracellular matrix protein. FGF9 significantly increased the number of cells that migrated to the bottom layer in a dose dependent manner (Figure 2) , and the effects were suppressed by treatment with anti-FGF9 neutralizing antibody (Figure 3) .
To determine the ability of FGF9 to induce anti-matrix metalloproteinase family, immunoblotting studies were conducted using LNCaP cells incubated in medium with or without FGF9 for 1, 3 and 5 days, respectively. The results showed that expression of MMP2 protein were induced by treatment with recombinant FGF9 for 3 and 5 days (Figure 4) .
These data suggest that FGF9 can enhance cell proliferation and cell invasion in prostate cancer cells.
Accumulation of FGF9 in cytoplasm increased in poorly differentiated prostate cancer cells
A total of 133 samples were obtained from patients that underwent radical prostatectomy owing to a diagnosis of prostate cancer with no prior therapy. Immunoreactivity of FGF9 was detected in 20 samples (15.0%). FGF9 was detected in the cytoplasm in some poorly differentiated adenocarcinoma cells, but not in any non-malignant Table 1 shows the relationship between the clinicopathological findings and prevalence of FGF9-positive tissues. All cases were divided into an FGF9-positive group and FGF9-negative group based on the detection of with FGF9 in the cytoplasm of prostate cancer cells by immunohistochemical staining. There was no significant difference between these two groups in the age, percentage of positive surgical margin and capsular penetration, venous invasion and microlymphovascular invasion.
The prevalence of FGF9-positive cells were significantly higher in cases diagnosed with a Gleason score of 8 or higher, with seminal vesicle invasion or whose serum PSA level was higher than 10 ng ml À1 in comparison with other cases (Table 1) . Furthermore, we examined and N-cadherin in FGF9-positive prostate tissues using immunohistochemical staining. Immunoreactivity of N-cadherin was detected in 15 (75%) of FGF9-positive samples (data not shown).
FGF9-positive prostate cancer showed higher risk of biochemical recurrence after radical prostatectomy Figure 5 shows the relationship between the biochemical relapse-free rate after surgery and the presence of FGF9-positive cells. The 3-year biochemical relapse-free rate was 75.5% in cases, which were free from FGF9-positive cells (FGF9-negative group), significantly higher than that in cases with FGF9-positive cells (designated as FGF9-positive group, 17.5%, Po0.0001 Figure 5a ). Biochemical relapse-free rates were also evaluated based on the patients' Gleason score, as the prevalence of FGF9-positive cells were significantly higher in specimens diagnosed with a Gleason score of 8 or higher in comparison with those with a Gleason score of 7 or lower (Figures 5b and c) . The 3-year biochemical relapsefree rate was 81.3% in FGF9-negative cases with a Gleason score of 7 or lower, significantly higher than that in the FGF9-positive group (21.4%, P ¼ 0.0002). The 3-year biochemical relapse-free rate was 58.5% in FGF9 in recurrence after radical prostatectomy J Teishima et al FGF9-negative cases with a Gleason score of 8 or higher, significantly higher than that in the FGF9-positive group (15.4%, P ¼ 0.0037). A univariate analysis revealed that initial PSA (Po0.0001), Gleason score (P ¼ 0.0004), positive surgical margin (P ¼ 0.006), capsular invasion (P ¼ 0.0021), perineural invasion (P ¼ 0.0459), venous invasion (P ¼ 0.0037), lymphovascular invasion (P ¼ 0.0207), seminal vesicle invasion (P ¼ 0.0049) and FGF9-positive (Po0.0001) were significant prognostic factors for biochemical relapse-free survival (Table 2) . A Cox proportional hazards multivariate model was used to examine the association of clinicopathological factors and FGF9-positive immunostaining with biochemical relapse-free survival. As shown in Table 2 , the multivariate analysis demonstrated that the presence of FGF9-positive cells, initial PSA and seminal vesicle invasion were independent predictive factors for biochemical recurrence after radical prostatectomy.
Discussion
FGF9 is known as glia-activating factor, 15 and is involved in numerous processes, such as differentiation of soft tissues 16 and testis, 17 sex determination, 18 angiogenesis and osteogenesis in long bone repair. 19 Furthermore, FGF9 has an important role in the progression of several malignant diseases. [4] [5] [6] 11 However, no study has demonstrated a correlation of FGF9 with biochemical recurrence after radical prostatectomy. The present findings demonstrate that FGF9 enhances proliferation and invasiveness in prostate cancer cells in vitro and the presence of FGF9-positive cancer cells shows a positive correlation with postoperative recurrence in prostate cancer. This study is the first report to reveal the novel role of FGF9 in promoting postoperative recurrence by accelerating proliferation and invasion of prostate cancer.
FGF9 is a key molecule in the formation of osteoplastic bone metastasis in androgen receptor-negative prostate cancer cells. 11 Furthermore, previous studies suggested the involvement of the FGF family, including FGF9 is associated with homeostasis of prostate tissue, and abnormalities of the FGF-FGF receptor pathway in prostate cancer.
1,2 The current study investigated that FGF9 had an important role in the progression of prostate cancer beyond the formation of bone metastasis. On the other hand, several studies have reported that FGF9 promotes cell proliferation. Klein et al. 20 demonstrated that members of the FGF family, including FGF9, induce the expression of promatrilysin in prostate cancer cells. Induction of MMP2 expression by the FGF family was reported in glioma cells. 21 Furthermore, FGF9 enhances cancer cell invasiveness induced by benzopyrene. 12 These findings suggest that FGF9 can accelerate proliferation and invasiveness of prostate cancer cells. The current study investigated the effects of FGF9 in prostate cancer cells. FGF9-enhanced cell proliferation ( Figure 1 ) and cell invasion (Figures 2 and 3) , and induced MMP2 expression in LNCaP cells (Figure 4) . The current results suggest that FGF9 can enhance the migration or metastasis of prostate cancer cells.
The localization of FGF9 in prostate cancer cells was determined in clinical samples obtained from radical prostatectomy. The immunohistochemical staining shown in Figure 5 revealed that FGF9 accumulated in the cytoplasm in many poorly differentiated adenocarcinoma cells. In addition, the detection of FGF9-positive cells was significantly higher in cases with a PSA level higher than 10 ng ml À1 , a Gleason score of 8 or higher, or positive seminal vesicle invasion (Table 1) . These findings indicate that there were FGF9-positive cells in highrisk prostate cancer tissues that had high potential for Table 2 , the presence of FGF9-positive cells was one of the independent prognostic factors for biochemical recurrence after radical prostatectomy. Prostate cancer tissues contain various cellular components. Therefore, the current data indicate the possibility that FGF9 is a marker of cells with high proliferative and invasive activity. The present study observed the immunohistochemical staining of only one representative section in every patient, and those that contained FGF9-positive cells, regardless of those volume or number, were classified as the FGF9-positive group. There were very small areas of FGF9-positive cells in some specimens of the FGF9-positive group. Previous studies have shown that a small percentage of tertiary Gleason grade 5 patterns in radical prostatectomy specimens with Gleason score 7 is a powerful predictive factor of biochemical recurrence after surgery. 22, 23 In addition, the expression of other factors in small areas of prostatectomy specimens is also predictive of the aggressiveness of prostate cancer. For instance, a recent study demonstrated the expression of regenerating islet-derived family member 4 induces phosphorylation of epidermal growth factor receptor, in specimens derived from radical prostatectomy. 13 The presence of regenerating islet-derived family member 4-positive cells is an independent prognostic marker for postoperative recurrence. These findings are similar to the immunohistochemical staining for FGF9 in the present study. This suggests that a small population of cells with aggressive pathological feature, such as FGF9-positive cells, may have a crucial role in the postoperative recurrence of prostate cancer. Figure 5 shows that most FGF9-positive cancer cells were detected in poorly differentiated adenocarcinoma tissues; however, FGF9 is strongly expressed in stromal cells in both benign and malignant tissues. [4] [5] [6] 11 These findings are consistent with previous studies of other malignant diseases. There may be a significant level of FGF9 in benign tissue. Harada et al. 24 reported that abnormal distribution of FGF9 caused failure of elbow and knee joint differentiation through abnormal FGF9 signaling, suggesting that the localization of FGF9 may be more important than the concentration of FGF9 in tissues. The current results suggest that accumulation of FGF9 in the cytoplasm may cause abnormal signaling and prostate cancer cells may gain enhanced aggressiveness through signaling generated by the abnormal accumulation of FGF9 in the cytoplasm. On the other hand, immunoreactivity of N-cadherin was detected in 75% of FGF9-positive tissue, suggesting that FGF9 may associate epithelial-mesenchymal transition in prostate cancer cells. Further studies should investigate the molecular mechanisms of FGF9 accumulation in cytoplasm and the abnormal signaling in cancer cells.
In summary, accumulation of FGF9 in prostate cancer cells accelerates cell proliferation and cell invasion, and may associate with biochemical recurrence after radical prostatectomy. The present study suggests that FGF9 may be predictive of recurrence after radical prostatectomy. Further study is necessary to determine any clinical applications of FGF9 accumulation in prostate cancer cells.
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